Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP) and RedHill Biopharma (RDHL).
Corbus Pharmaceuticals (CRBP)
In a report issued on October 6, Brian Abrahams from RBC Capital maintained a Hold rating on Corbus Pharmaceuticals, with a price target of $2.00. The company’s shares closed last Monday at $1.14, close to its 52-week low of $1.04.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.3% and a 49.6% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
Corbus Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $2.18, implying a 78.7% upside from current levels. In a report issued on October 6, Roth Capital also maintained a Hold rating on the stock with a $1.22 price target.
See today’s analyst top recommended stocks >>
RedHill Biopharma (RDHL)
SMBC Nikko analyst David Hoang maintained a Buy rating on RedHill Biopharma on September 30 and set a price target of $19.00. The company’s shares closed last Monday at $9.96.
According to TipRanks.com, Hoang is ranked #5410 out of 7014 analysts.
Currently, the analyst consensus on RedHill Biopharma is a Strong Buy with an average price target of $20.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RDHL:
